JAK2

(redirected from Janus kinase 2)
Also found in: Wikipedia.

JAK2

A gene on chromosome 9p24 that encodes a non-receptor protein tyrosine kinase, which is involved in a subset of cytokine receptor signalling pathways, including for cell growth, development, differentiation and histone modifications. JAK2 mediates essential signalling events in both innate and adaptive immunity, and is required for responses to gamma interferon. It plays a key role in signal transduction by associating with type-I receptors (e.g., growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO)) or type-II receptors (e.g., IFN-alpha, IFN-beta, IFN-gamma and a wide range of interleukins).
References in periodicals archive ?
Our previous work showed that the expression of HMGB1, a late inflammatory factor, can be induced by trypsinogen activation peptide (an early pro-inflammatory cytokine) in rat pancreatic acinar cells and tissues [8,9], and the induction process may involve the Janus kinase 2 and signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway in pancreatic acinar cells [10].
AR-13154 targets Rho Kinase, Janus Kinase 2, and platelet-derived growth factor receptor beta.
In 2005 James et al (3) described a specific acquired point mutation in the Janus kinase 2 gene (JAK2) in PV.
The CALR diagnostic test is expected to be a strong fit to QIAGEN's kits for a key mutation of the Janus kinase 2 (JAK2) gene.
This early stage investigational compound, called JAK2 inhibitor, is currently being developed by Lilly that targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.
TareGen's TG101348 aims to block the effects of an enzyme known as Janus kinase 2, Sanofi said.
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.
a leading national provider of physician-based anatomic pathology, has developed a new assay that detects and quantifies a mutation in the Janus kinase 2 (JAK2) gene common in bcr/abl-negative myeloproliferative disorders (MPDs).
The companies have previously partnered on developing tailored therapies in cancer and other therapeutic areas, as well as on a companion diagnostic assessing the Janus kinase 2 (JAK2) gene, when combined with Eli Lilly's compound to guide use of the proposed drug, currently being evaluated in clinical studies.
Lilly's proprietary compound, a JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.